NCT07693543 Matched Placebo (Capsules) Chronic Kidney Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07693543—Nicotinamide Riboside Supplementation in Chronic Kidney Disease (NR-CKD)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07693543 is a hot trial to watch
Chronic Kidney Diseases is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07693543 is notable because it evaluates Matched Placebo (Capsules) in a Phase 2 design while Change in plasma cell-free mitochondrial DNA concentration, measured as mitochondrial DNA copies per mL of plasma using droplet digital PCR. serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07693543 |
| Official title | Nicotinamide Riboside Supplementation in Chronic Kidney Disease (NR-CKD) |
| Phase / status | Phase 2 / Not yet recruiting |
| Intervention | Matched Placebo (Capsules), Nicotinamide Riboside (NR) |
| Sponsor | University of California San Diego |
| Collaborators | Not reported |
| Geography | United States |
| Enrollment | 30 |
| Primary endpoint | Change in plasma cell-free mitochondrial DNA concentration, measured as mitochondrial DNA copies per mL of plasma using droplet digital PCR. |
| Endpoint time frame | Baseline, Week 12, and Week 26 |
| Primary completion / readout proxy | [object Object] |
Design and endpoint interpretation
The phase label is only the starting point. Allocation is Randomized, masking is Triple, and the intervention model is Crossover Assignment. Planned enrollment of 30 participants across United States shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary: Change in plasma cell-free mitochondrial DNA concentration, measured as mitochondrial DNA copies per mL of plasma using droplet digital PCR. (Baseline, Week 12, and Week 26)
- Primary: Change in urine cell-free mitochondrial DNA concentration, measured using droplet digital PCR and reported as mitochondrial DNA copies normalized to urine osmolarity. (Baseline, Week 12, and Week 26)
- Secondary: Change in skin capillary density, measured as capillaries per mm2 using capillaroscopy. (Baseline, Week 12, and Week 26)
- Secondary: Change in skin blood flow, measured in laser Doppler perfusion units using laser Doppler flowmetry. (Baseline, Week 12, and Week 26)
- Secondary: Change in distance walked during the six-minute walk test, measured in meters. (Baseline, Week 12, and Week 26)
Benchmark readouts in the surrounding field
- An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol® (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis (Phase 3): Percentage of Participants Who Achieved 2 Consecutive >=30% Reductions in Intact Parathyroid Hormone From Baseline up to Week 12: Perecntage difference = -52.9(95% CI, -99.90 to -5.98); Percentage of Participants Who Achieved 2 Consecutive >=30% Reductions in Intact Parathyroid Hormone From Baseline up to Week 12 = 71.4 percentage of participants (95% Confidence Interval, 29.04 - 96.33)
- A Phase IIb, Multicenter, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination With Dapagliflozin Compared With Dapagliflozin in Patients With Chronic Kidney Disease and Albuminuria (Phase 2): Relative Change in Urine Albumin-to-Creatinine Ratio (UACR) From Baseline to Week 12(Geometric Least Squares Mean) = 0.66 mg/g (90% Confidence Interval, 0.59 - 0.73); Relative Change in Urine Albumin-to-Creatinine Ratio (UACR) From Baseline to Week 12(Geometric Least Squares Mean): Percent change difference = -32.77(90% CI, -41.96 to -22.14), P-Value = <0.001; Percent Change Difference = -22.83(90% CI, -33.34 to -10.66), P-Value = 0.0038
- 1394-P: Impact of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Levels and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial (Phase 2): UACR(6-month): P-Value = 0.0001; UACR(6-month): P-Value = 0.0001
These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.
Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Not reported
Company & Deal Intelligence context: University of California San Diego — United States — http://www.ucsd.edu
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.
Bottom line
NCT07693543 is a focused lens on Chronic Kidney Diseases development. Its value will be determined by whether Matched Placebo (Capsules) can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
